<DOC>
	<DOC>NCT00082589</DOC>
	<brief_summary>The purpose of this study is to determine if eplerenone is effective in the treatment of mild to moderate heart failure</brief_summary>
	<brief_title>The Purpose of This Study is to Determine if Eplerenone is Effective in Treatment of Mild to Moderate Heart Failure</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Eplerenone</mesh_term>
	<mesh_term>Spironolactone</mesh_term>
	<criteria>Current symptoms consistent with mild to moderate heart failure (NYHA functional class II and III) LVEF (left ventricular ejection fraction) of &lt;35% by equilibriumgated RVG at screening Therapy with an angiotensin converting enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB) and betablocker (BB) (unless documented intolerance) for at least 3 months duration and at dose that has not been adjusted within the previous 4 weeks Current decompensated heart failure or heart failure hospitalization or severe heart failure (NYHA functional class IV) within 6 months of screening Use of eplerenone or spironolactone within 30 days of randomization or for more than 7 days within the previous 6 months</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2007</verification_date>
</DOC>